OM
NVLN

Opaleye Management’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Opaleye Management’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-750,000
Closed -$6.92M – 46
2017
Q2 		$6.92M Buy
750,000
+20,000
+3% +$193K 2.89% 12
2017
Q1 		$7.84M Buy
+730,000
New +$7.46M 3.9% 4

Other funds holding NVLN

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Opaleye Management's NVLN Position: Q3 2017 in Review

Opaleye Management sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q3 2017, closing a stake of 750,000 shares — an estimated $6.92M sold.

Opaleye Management first reported a position in NVLN in Q1 2017 and held it in 2 quarters. The position peaked at $7.84M in Q1 2017. 72 funds tracked by Wall St. Rank hold NVLN as of Q3 2017.

  • Opaleye Management reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q3 2017 after selling out during the quarter.
  • Opaleye Management sold 750,000 Novelion Therapeutics Inc. Common Shares shares in Q3 2017, an estimated $6.92M.
  • Opaleye Management first reported a position in Novelion Therapeutics Inc. Common Shares in Q1 2017 and held it in 2 quarters.
  • Opaleye Management's Novelion Therapeutics Inc. Common Shares position peaked at $7.84M in Q1 2017.
  • 72 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q3 2017.

Based on Opaleye Management's 13F filing for Q3 2017, filed 14 Nov 2017.